Selskabsmeddelelse11.12.2025, 10.45Diagonal Bio intends to submit a formal application for bankruptcy
Selskabsmeddelelse31.10.2025, 08.00Diagonal Bio publishes interim report for the third quarter of 2025
Pressemeddelelse13.10.2025, 09.00Diagonal Bio launches new website to reflect commercial focus on the Animal Health segment
Pressemeddelelse03.10.2025, 11.30Diagonal Bio initiates collaboration with SVA on evaluation of coronavirus in horses
Selskabsmeddelelse23.09.2025, 11.15Diagonal Bio expands horse testing panel to detect Equine Herpesvirus type 2
Selskabsmeddelelse22.08.2025, 08.00Diagonal Bio publishes interim report for the second quarter of 2025
Pressemeddelelse07.07.2025, 13.00Diagonal Bio AB files patent application for Novel Computational Method that significantly improves LAMP primer design
Selskabsmeddelelse25.06.2025, 13.00The Board of Directors of Diagonal Bio carries out a directed issue to underwriters in connection with exercise of warrants of series TO 2
Selskabsmeddelelse19.06.2025, 13.40Diagonal Bio receives SEK 3.6 million through exercise of warrants of series TO 2
Selskabsmeddelelse17.06.2025, 18.47Update regarding large shareholder’s exercise of warrants of series TO 2
Selskabsmeddelelse13.06.2025, 08.00Last day of trading in Diagonal Bio’s warrants of series TO 2 is 16 June 2025
Selskabsmeddelelse09.06.2025, 14.00Svea Bank AB invests SEK 0.5 million in Diagonal Bio AB through the exercise of warrants of series TO 2